valdecoxib


Also found in: Dictionary, Thesaurus, Wikipedia.
Related to valdecoxib: rofecoxib, Parecoxib

valdecoxib

/val·de·cox·ib/ (val″dĕ-kok´sib) a nonsteroidal antiinflammatory drug of the COX-2 inhibitors group, used for the treatment of osteoarthritis, rheumatoid arthritis, and primary dysmenorrhea.

valdecoxib

a nonsteroidal antiinflammatory used to treat acute and chronic rheumatoid arthritis, osteoarthritis, and primary dysmenorrhea.

Bextra

A next-generation NSAID Cox-2 inhibitor used for managing pain due to osteoarthritis, rheumatoid arthritis, dysmenorrhea, etc.
 
Adverse effects
Rarely, serious skin and hypersensitivity reactions (e.g., Stevens Johnson syndrome); toxic epidermal necrolysis; exfoliative dermatitis; erythema multiforme, possibly requiring hospitalisation; Bextra is contraindicated with sulfa drugs.

valdecoxib

See Bextra®.

valdecoxib

A COX-2 inhibitor drug used to treat OSTEOARTHRITIS, RHEUMATOID ARTHRITIS and DYSMENORRHOEA. A brand name is Bextra. In late 2004 the drug was shown to have cardiotoxic properties similar to those of rofecoxib and it was recommended that the drug should be withdrawn.
References in periodicals archive ?
The COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trial.
The committee recommended that celecoxib and valdecoxib may remain on the market with black box warnings regarding the cardiovascular risks.
Rofecoxib was voluntarily withdrawn from the market in September 2004 and valdecoxib was withdrawn in April of 2005, and these events affected physician prescribing habits.
NSAIDs such as valdecoxib are known to provide effective analgesia when used for dysmenorrhoea1.
Ott E, Nussmeier NA, Duke PC 2003 Efficacy and safety of the cyclo-oxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary bypass surgery Journal of Thoracic and Cardiovascular Surgery 125 1481-1492
75 [micro]g/ml of TAM and 2 [micro]g/ml of valdecoxib as internal standard.
Rofecoxib and valdecoxib, highly selective COX-2 inhibitors, were recently withdrawn from the market because of adverse effects.
3) Another meta-analysis of two trials in high-risk patients taking valdecoxib who had recently undergone coronary artery bypass surgery, showed a significant 3-fold increase in cardiovascular events.
Ever since reports of sudden heart attack and stroke prompted rofecoxib (Vioxx) and valdecoxib (Bextra) to be taken off the market, other nonsteroidal anti-inflammatory drugs (NSAIDs) have been living under a shadow.
Evaluation of preemptive valdecoxib therapy on initial archwire placement discomfort in adults.
Food and Drug Administration, Pfizer withdrew another COX-2 drug, valdecoxib Bextra), from the market after studies showed an increased risk of heart attack, stroke and other cardiovascular problems in people taking the drug for postoperative pain after coronary artery bypass surgery.
In November 2001, the FDA granted approval to Pfizer for its COX-2 inhibitor valdecoxib (Bextra) for three uses (menstrual pain, rheumatoid arthritis, and osteoarthritis), but rejected its application for acute pain.